Merger Notification - Announcement according to § 10 Cartel Act
Karo Pharma AB; Teva Gruppe
BWB/Z-5257
On 11.02.2021 the Austrian Federal Competition Authority was notified of the following merger:
Planned purchase process
Karo Pharma AB (Sweden) intends to acquire certain assets of the Teva group related to the Decubal, Flux, Apobase and Lactocare product lines and the product Fludent. The proposed concentration concerns cosmetic products, food supplement products, and pharmaceutical product.
Affected business areas: Manufacture of basic pharmaceutical products and pharmaceutical preparations
Industry sector: C - Verarbeitendes Gewerbe/Herstellung von Waren
Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 11.03.2021.
Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.
Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.
Non-prohibition of the merger
The Federal Competition Authority and the Federal Cartel Prosecutor have not applied for examination of the merger by the Cartel Court. The standstill obligation (§ 17 (1) Cartel Act) ends with effect from 12.03.2021 .